Avenue Therapeutics Inc (NASDAQ: ATXI)’s stock price has gone decline by -18.24 in comparison to its previous close of 0.95, however, the company has experienced a -22.70% decrease in its stock price over the last five trading days. globenewswire.com reported 2024-11-14 that – Topline data in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy anticipated around year-end 2024 – Topline data in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy anticipated around year-end 2024
Is It Worth Investing in Avenue Therapeutics Inc (NASDAQ: ATXI) Right Now?
Moreover, the 36-month beta value for ATXI is -0.20. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ATXI is 1.74M and currently, short sellers hold a 3.43% of that float. On March 14, 2025, ATXI’s average trading volume was 412.91K shares.
ATXI’s Market Performance
ATXI’s stock has seen a -22.70% decrease for the week, with a -43.58% drop in the past month and a -57.76% fall in the past quarter. The volatility ratio for the week is 10.67%, and the volatility levels for the past 30 days are at 7.60% for Avenue Therapeutics Inc The simple moving average for the past 20 days is -33.21% for ATXI’s stock, with a -66.95% simple moving average for the past 200 days.
ATXI Trading at -46.79% from the 50-Day Moving Average
After a stumble in the market that brought ATXI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -94.35% of loss for the given period.
Volatility was left at 7.60%, however, over the last 30 days, the volatility rate increased by 10.67%, as shares sank -41.44% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -60.15% lower at present.
During the last 5 trading sessions, ATXI fell by -22.70%, which changed the moving average for the period of 200-days by -78.65% in comparison to the 20-day moving average, which settled at $1.1573. In addition, Avenue Therapeutics Inc saw -61.35% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ATXI starting from Herskowitz Neil, who sale 23 shares at the price of $2.00 back on Dec 02 ’24. After this action, Herskowitz Neil now owns 97 shares of Avenue Therapeutics Inc, valued at $46 using the latest closing price.
KRANZLER JAY D, the Director of Avenue Therapeutics Inc, sale 61 shares at $2.24 during a trade that took place back on Nov 05 ’24, which means that KRANZLER JAY D is holding 559 shares at $137 based on the most recent closing price.
Stock Fundamentals for ATXI
The total capital return value is set at -7.15. Equity return is now at value -1037.72, with -893.00 for asset returns.
Currently, EBITDA for the company is 4.05 million with net debt to EBITDA at 0.85. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.70.
Conclusion
To wrap up, the performance of Avenue Therapeutics Inc (ATXI) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
